Navigation Links
Watson Launches Generic PROMETRIUM(R)
Date:3/2/2012

PARSIPPANY, N.J., March 2, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Watson has launched an authorized generic version of PROMETRIUM® (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories. Watson began shipping the product today. PROMETRIUM® Capsules are indicated for use in the prevention of endometrial hyperplasia in non hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. They are also indicated for use in secondary amenorrhea.

Under the terms of the supply agreement, Abbott manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States and the parties will share profits based on sales of the product. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending January 31, 2012, PROMETRIUM® had sales of approximately $198 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets. 

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to no
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson to Present at the Barclays Capital 2012 Global Healthcare Conference
2. Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%
3. Watson to Present at the 2012 RBC Capital Markets Healthcare Conference
4. Watson to Present at the Citi 2012 Global Healthcare Conference
5. Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;
6. Watson Provides Update on Generic Lidoderm® Application
7. Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
8. Watson Confirms Court Stays Preliminary Injunction
9. Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
10. Watson Acquires Ascent Pharmahealth for AU$375 Million
11. Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
(Date:8/31/2015)... ... August 31, 2015 , ... In an article published August 24th ... Global Open Journal that discusses the future of 3-D printing technology as it relates ... customized implants, prosthetics, and other 3-D printed tools could be used to aid in ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... Replacement Surgery Program at Monmouth, was one of the first doctors in the ... results of this new approach have been impressive: faster recovery, decreased immediate and ...
(Date:8/31/2015)... ... , ... Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center is ... all surgical and non-surgical disorders of the leg, ankle and foot. He also ... spine. , Dr. Paul Kovatis completed his orthopedic leg, ankle and foot fellowship training ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can ... others—to hold down costs? , In a commentary for The American Journal ... the concept of “clinical efficacy,” which would bind parties together in agreements to ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... 2015 ABBY Awards, at the 16th Innovations in Healthcare(SM) Awards Event , ... Adaptive Business Leaders (ABL) Organization , recognizes innovative organizations and individuals who are ...
Breaking Medicine News(10 mins):Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8
... DUBLIN, Ohio, Feb. 17 Cardinal Health today,announced it ... (FDA),on an amended consent decree regarding the company,s infusion ... has operated under a consent decree since February 2007,for ... implementing a new,quality system on April 2, 2008. Under ...
... too much TV is linked to poorer recall, study finds ... such as reading or playing games, in middle age and ... new research. , The study included 197 people, ages 70 ... and 1,124 people in the same age group with no ...
... Fla. Vitamin supplements can prevent hearing loss in ... one step closer to the development of a pill ... hearing loss in humans. , The findings will be ... annual conference in Baltimore by senior author Colleen Le ...
... INDIANAPOLIS, Feb. 17 WellPoint, Inc.,(NYSE: WLP ... webcast of its,Investor Conference on Tuesday, February 24, 2009. ... and chief executive officer of WellPoint, Inc.,and will feature ... The event is scheduled to ...
... 23 PERCENTSAN DIEGO, Feb. 17 Volcano Corporation (Nasdaq: ... manufacturing and sales of products for the diagnosis and ... that revenues for the full year 2008 increased 31 ... the fourth quarter of 2008 increased 23 percent over ...
... declines of up to 70 percent, CDC researchers say, ... caused by methicillin-resistant Staphylococcus aureus (MRSA) have ... the U.S. Centers for Disease Control and Prevention report. ... to certain antibiotics, can cause severe infections in people ...
Cached Medicine News:Health News:Cardinal Health, FDA Amend Infusion Pump Consent Decree 2Health News:Reading, Games Help Keep Aging Memories Sharp 2Health News:Vitamin supplements may protect against noise-induced hearing loss 2Health News:Vitamin supplements may protect against noise-induced hearing loss 3Health News:WellPoint Announces Webcast of its Conference with Investment Community 2Health News:Volcano Reports Full Year Revenues Increase 31 Percent 2Health News:Volcano Reports Full Year Revenues Increase 31 Percent 3Health News:Volcano Reports Full Year Revenues Increase 31 Percent 4Health News:Volcano Reports Full Year Revenues Increase 31 Percent 5Health News:Volcano Reports Full Year Revenues Increase 31 Percent 6Health News:Volcano Reports Full Year Revenues Increase 31 Percent 7Health News:Volcano Reports Full Year Revenues Increase 31 Percent 8Health News:Volcano Reports Full Year Revenues Increase 31 Percent 9Health News:Volcano Reports Full Year Revenues Increase 31 Percent 10Health News:Volcano Reports Full Year Revenues Increase 31 Percent 11Health News:Volcano Reports Full Year Revenues Increase 31 Percent 12Health News:Volcano Reports Full Year Revenues Increase 31 Percent 13Health News:Volcano Reports Full Year Revenues Increase 31 Percent 14Health News:MRSA Cases Dropping in Hospital ICUs 2Health News:MRSA Cases Dropping in Hospital ICUs 3Health News:MRSA Cases Dropping in Hospital ICUs 4
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: